基于磁共振成像与前列腺特异性膜抗原正电子发射断层显像的列线图预测前列腺癌盆腔淋巴结转移概率的开发与外部验证
研究纳入700例建模队列和305例外部队列的前列腺癌患者,开发了纳入初始PSA、MRI T分期、活检分级组、活检技术、系统穿刺阳性针百分比及PSMA-PET淋巴结状态的Amsterdam-Brisbane-Sydney列线图,预测pN状态的AUC为0.81(95%CI 0.78-0.85),外部验证AUC为0.75(95%CI 0.69-0.81),优于Briganti-2017和MSKCC列线图,与Briganti-2019列线图相似。
要点
- Amsterdam-Brisbane-Sydney列线图纳入PSA、MRI T分期、活检GG、活检技术、系统穿刺阳性针百分比和PSMA-PET淋巴结状态。
- 建模队列AUC 0.81(95%CI 0.78-0.85),外部验证AUC 0.75(95%CI 0.69-0.81)。
- 外部验证中优于Briganti-2017和MSKCC列线图,与Briganti-2019列线图相似。
核心结论
- 经验证的Amsterdam-Brisbane-Sydney列线图预测pN状态的表现优于Briganti-2017和MSKCC列线图,与Briganti-2019列线图相似。
- 该列线图适用于所有新诊断的不利中危和高危前列腺癌患者。
研究设计与样本
- 模型构建队列纳入700例接受机器人辅助根治性前列腺切除术和扩大盆腔淋巴结清扫的合格患者。
- 外部验证队列由305例接受手术治疗的患者组成。
- 采用后向消除法的逻辑回归选择变量构建Amsterdam-Brisbane-Sydney列线图。
主要发现
- 最终模型预测pN状态的AUC为0.81(95%CI 0.78-0.85)。
- 外部验证中Amsterdam-Brisbane-Sydney列线图AUC为0.75(95%CI 0.69-0.81),Briganti-2017列线图AUC为0.67(95%CI 0.61-0.74),MSKCC列线图AUC为0.65(95%CI 0.58-0.72),差异p < 0.05。
- 外部验证中Amsterdam-Brisbane-Sydney列线图AUC为0.78(95%CI 0.71-0.86),Briganti-2019列线图AUC为0.80(95%CI 0.73-0.86),差异p = 0.76。
- 外部验证中Amsterdam-Brisbane-Sydney列线图显示优秀校准,在阈值概率≥4%时净获益增加。
关键数值与推荐
- Amsterdam-Brisbane-Sydney列线图纳入初始前列腺特异性抗原值、MRI T分期、最高活检分级组、活检技术、系统穿刺针中临床显著前列腺癌(GG≥2)的百分比以及PSMA-PET淋巴结状态。
临床怎么用
- 术前评估pN1概率用于识别适合扩大盆腔淋巴结清扫的前列腺癌患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Preoperative assessment of the probability of pelvic lymph-node metastatic disease (pN1) is required to identify patients with prostate cancer (PCa) who are candidates for extended pelvic lymph-node dissection (ePLND). OBJECTIVE: To develop a novel intuitive prognostic nomogram for predicting pathological lymph-node (pN) status in contemporary patients with primary diagnosed localized PCa, using preoperative clinical and histopathological parameters, magnetic resonance imaging (MRI), and prostate-specific membrane antigen (PSMA) positron emission tomography (PET). DESIGN, SETTING, AND PARTICIPANTS: In total, 700 eligible patients who underwent robot-assisted radical prostatectomy and ePLND were included in the model-building cohort. The external validation cohort consisted of 305 surgically treated patients. Logistic regression with backward elimination was used to select variables for the Amsterdam-Brisbane-Sydney nomogram. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Performance of the final model was evaluated using the area under the receiver operating characteristic curve (AUC), calibration plots, and decision-curve analyses. Models were subsequently validated in an external population. RESULTS AND LIMITATIONS: The Amsterdam-Brisbane-Sydney nomogram included initial prostate-specific antigen value, MRI T stage, highest biopsy grade group (GG), biopsy technique, percentage of systematic cores with clinically significant PCa (GG ≥2), and lymph-node status on PSMA-PET. The AUC for predicting pN status was 0.81 (95% confidence interval [CI] 0.78-0.85) for the final model. On external validation, the Amsterdam-Brisbane-Sydney nomogram showed superior discriminative ability to the Briganti-2017 and Memorial Sloan Kettering Cancer Center (MSKCC) nomograms (AUC 0.75 [95% CI 0.69-0.81] vs 0.67 [95% CI 0.61-0.74] and 0.65 [95% CI 0.58-0.72], respectively; p < 0.05), and similar discriminative ability to the Briganti-2019 nomogram (AUC 0.78 [95% CI 0.71-0.86] vs 0.80 [95% CI 0.73-0.86]; p = 0.76). The Amsterdam-Brisbane-Sydney nomogram showed excellent calibration on external validation, with an increased net benefit at a threshold probability of ≥4%. CONCLUSIONS: The validated Amsterdam-Brisbane-Sydney nomogram performs superior to the Briganti-2017 and MSKCC nomograms, and similar to the Briganti-2019 nomogram. Furthermore, it is applicable in all patients with newly diagnosed unfavorable intermediate- and high-risk PCa. PATIENT SUMMARY: We developed and validated the Amsterdam-Brisbane-Sydney nomogram for the prediction of prostate cancer spread to lymph nodes before surgery. This nomogram performs similar or superior to all presently available nomograms.
引用
- Vis AN, Meijer D, Roberts MJ, et al. Development and External Validation of a Novel Nomogram to Predict the Probability of Pelvic Lymph-node Metastases in Prostate Cancer Patients Using Magnetic Resonance Imaging and Molecular Imaging with Prostate-specific Membrane Antigen Positron Emission Tomography. Eur Urol Oncol. 2023. PMID: 37045707. doi:10.1016/j.euo.2023.03.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。